Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Dear Mr President...

Flight Centre Travel
3:27pm
April 28, 2025
Given recent downgrades from other travel/airline industry peers due to political and macro-economic uncertainty, FLT’s downgrade wasn’t a surprise. The mid-point of new guidance now implies that 2H25 will be weaker than the 2H24. Given its balance sheet strength and depressed share price, the up to A$200m share buyback is a good use of FLT’s excess capital and is nicely EPS accretive. Due to all the uncertainty, the question is whether operating conditions will get worse before they get better. However, what we do know from past economic and geopolitical events, is that after a downturn, travel demand rebounds. We are buyers of FLT during this period of short term uncertainty and share price weakness because when operating conditions ultimately improve, both its earnings and share price leverage to the upside will be material.

Demand starting to soften

Brambles
3:27pm
April 28, 2025
BXB’s 3Q25 trading update overall was slightly weaker than expected with year-to-date (YTD) constant FX sales rising 3% vs our 5% forecast. While management reiterated FY25 constant FX underlying EBIT growth guidance of between 8-11%, sales growth guidance was narrowed to 4-5% (vs 4-6% previously). FY25 free cash flow (before dividends) guidance was increased to between US$900-1,000m (vs US$850-950m previously) due mainly to lower pooling capex on the back of softer like-for-like (LFL) volumes and better asset efficiency. We decrease FY25-27F underlying EBIT by 1% with reductions to constant FX estimates partially offset by updates to FX assumptions. We now forecast FY25 constant FX sales growth of 4% and underlying EBIT growth of 8%, which is at the lower end of management’s guidance ranges. Our target price declines to $19.75 (from $20.50) and we maintain our Hold rating.

Solid operationally, but balance sheet and lithium price create overhang

Liontown Resources
3:27pm
April 28, 2025
LTR posted a solid quarterly result with production and costs slightly ahead of market expectations. Cash declined by -10% to A$173m and net debt now sits at A$526m without including leases obligations. In our view, LTR’s balance sheet remains an issue should lithium prices remain at current levels or trend lower over the near term, which is becoming a higher possibility. We maintain our HOLD rating with a A$0.52ps TP (previously A$0.ps).

Strong value proposition intact

Mitchell Services
3:27pm
April 28, 2025
MSV’s value proposition remains intact despite some 3Q earnings slippage due to season disruption and a slower than expected rig-rollout. We trim our FY25-26 EBITDA forecasts by 11-18% and our valuation by 10% to 45cps, applying a more conservative multiple. FY25 shapes as a trough year for earnings as MSV re-deploys rigs and pivots into new segments. However, FY26 looks strongly set-up for higher earnings, cash conversion and a resumption of dividends. MSV remains too cheap on all value measures and suits patient investors.

3Q beat

ResMed Inc
3:27pm
April 27, 2025
3Q results were above expectations, with high-single digit revenue growth, expanding operating leverage, and strong cash flow. Sleep and respiratory sales were solid, with resupply and new patient set-ups supporting Americas mask growth, while ROW tracked the market and residential care software sales posted double-digit gains. GPM continues to surprise to the upside, underpinned by manufacturing efficiencies and favourable product mix, while OPM gained on good cost control. Importantly, RMD confirmed its tariff-exempt status, and when taken together with an expanding US manufacturing footprint, new technologies to drive adoption and added benefits from favourable trends in wearables and weight loss drugs, we continue to view the company in a strong competitive position. FY25-27 earnings increase up to 0.7%, with our target price rising to $44.07. Add.

Stellar start to 2025

Newmont Corporation
3:27pm
April 24, 2025
NEM achieved a strong production, cost and cash flow result in the 1Q helped by record high gold prices, which saw it achieve record free cash flow. Net debt reduced by -39% qoq as a result record cash flows and a ~US$1bn debt repayment. NEM has now bought back ~US$755m of its shares since the start of CY25 and expects to continue to do so for the remainder of this year and into CY26. We Maintain our ADD rating with a A$97ps TP (previously A$84ps).

Model update: Q1 traffic and toll revenue, FX rates

Atlas Arteria
3:27pm
April 23, 2025
We update our forecasts to reflect 1Q25 traffic and toll revenue data released by ALX. In addition, we update the AUDEUR and AUDUSD rates used in our modelling, with the decline in the spot AUDEUR particularly beneficial for ALX. Our modelling indicates ALX will have sufficient distributable cashflow and cash reserves to support at least 40 cps of annual DPS until at least the end of the decade. At current prices, this implies a cash yield of 8.1%. 12 month target price lifts 49 cps to $5.09/sh. Total potential 12 month return at current prices is c.11% (or c.4% ex IFM takeover potential). Assuming no corporate activity and given the APRR’s decaying equity value we estimate a 5 year investment IRR at current prices of c.7.0% pa. HOLD retained.

Spring in the step

Imricor Medical Systems
3:27pm
April 23, 2025
IMR has made an exciting start to CY25 which included a major step forward in interventional medicine with the first-in-human ventricular ablation procedure guided by real time MRI. IMR finished 1Q25 in a strong cash position following a A$70m capital raising. Cash receipts remain modest, however subsequent quarters are expected to see growth with the sales teams being strengthened and approvals secured for its 2nd generation Catheter in Europe. Upcoming catalysts include additional sales, clinical trial updates and approvals. We have made no changes to forecasts or valuation. We maintain our Speculative Buy recommendation.

Not now, but soon

Proteomics International Laboratories
3:27pm
April 23, 2025
PIQ has completed a A$4.5m placement to fund the commercial launch across its range of diagnostic tests in Australia and the US as well as upgrading systems and establishing laboratory platforms. The placement coincides with an SPP, aiming to raise a further A$1m. The placement addresses immediate cash concerns, although it appears insufficient to see the company through to meaningful commercial success. We believe that the in-house commercial rollout and reliance on out-of-pocket funding will hinder initial sales and thereby extend the timeframe to achieve meaningful revenues. Notwithstanding our longer-term view that there is substantial value in these tests, we view there is commercial risk, time, expenses, and likely another capital injection to wash through before the sales traction gets interesting. Happy to hold at these levels or add small positions on weakness for risk tolerant investors. Following our changes, our target price is reduced to A$0.43 p/s but we retain our Hold recommendation.

Steadies the ship, builds cash

South32
3:27pm
April 22, 2025
Solid quarter operationally, aside from Cannington’s downgrade, which was not altogether shocking from the aging mine. Net cash of US$252m highlights a strong capital position and solid resilience. Hermosa build and GEMCO restart are key growth levels, with broader portfolio largely in harvest mode – leaving South32 share price sensitive to metal prices. Maintain ADD rating with unchanged A$4.30 target price.

News & Insights

Michael Knox, Chief Economist looks at what might have happened in January 2026 if the cuts in corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill

In recent weeks, a number of media commentators have criticized Donald Trump's " One big Beautiful Bill " on the basis of a statement by the Congressional Budget Office that under existing legislation the bill adds $US 3.4 trillion to the US Budget deficit. They tend not to mention that this is because the existing law assumes that all the tax cuts made in 2017 by the first Trump Administration expire at the end of this year.

Let’s us look at what might have happened in January 2026 if the cuts in US corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill.

Back in 2016 before the first Trump administration came to office in his first term, the US corporate tax rate was then 35%. In 2017 the Tax Cut and Jobs Act reduced the corporate tax rate to 21%. Because this bill was passed as a "Reconciliation Bill “, This meant it required only a simple majority of Senate votes to pass. This tax rate of 21% was due to expire in January 2026.

The One Big Beautiful Bill has made the expiring tax cuts permanent; this bill was signed into law on 4 July 2025. Now of course the same legislation also made a large number of individual tax cuts in the original 2017 bill permanent.

What would have happened if the bill had not passed. Let us construct what economists call a "Counterfactual"

Let’s just restrict ourselves to the case of what have happened in 2026 if the US corporate tax had risen to the prior rate of 35%.

This is an increase in the corporate tax rate of 14%. This increase would generate a sudden fall in US corporate after-tax earnings in January 2026 of 14%. What effect would that have on the level of the S&P 500?

The Price /Earnings Ratio of the S&P500 in July 2025 was 26.1.

Still the ten-year average Price/ Earnings Ratio for the S&P500 is only 18.99. Let’s say 19 times.

Should earnings per share have suddenly fallen by 14%, then the S&P 500 might have fallen by 14% multiplied by the short-term Price/ Earnings ratio.

This means a likely fall in the S&P500 of 37%.

As the market recovered to long term Price Earnings ratio of 19 this fall might then have ben be reduced to 27%.

Put simply, had the One Big, beautiful Bill not been passed, then in 2026 the US stock market might suddenly have fallen by 37% before then recovering to a fall of 27% .

The devastating effect on the US and indeed World economy might plausibly have caused a major recession.

On 9 June Kevin Hassert the Director of the National Economic Council said in a CBS interview with Margaret Brennan that if the bill did not pass US GDP would fall by 4% and 6-7 million Americans would lose their jobs.

The Passage of the One Big Beautiful Bill on 4 July thus avoided One Big Ugly Disaster.

Read more
On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut, Michael Knox being one of them.

On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut on 8 July. I was one of them. The RBA did not cut.

So today I will talk about how I came to that decision. First, lets look at our model of official interest rates. Back in January 2015 I went to a presentation in San Franciso by Stan Fishcer . Stan was a celebrated economist who at that time was Ben Bernanke's deputy at the Federal Reserve. Stan gave a talk about how the Fed thought about interest rates.

Stan presented a model of R*. This is the real short rate of the Fed Funds Rate at which monetary policy is at equilibrium. Unemployment was shown as a most important variable. So was inflationary expectations.

This then logically lead to a model where the nominal level of the Fed funds rate was driven by Inflation, Inflationary expectations and unemployment. Unemployment was important because of its effect on future inflation. The lower the level of unemployment the higher the level of future inflation and the higher the level of the Fed funds rate. I tried the model and it worked. It worked not just for the Fed funds rate. It also worked in Australia for Australian cash rate.

Recently though I have found that while the model has continued to work to work for the Fed funds rate It has been not quite as good in modelling that Australian Cash Rate. I found the answer to this in a model of Australian inflation published by the RBA. The model showed Australian Inflation was not just caused by low unemployment, It was also caused by high import price rises. Import price inflation was more important in Australia because imports were a higher level of Australian GDP than was the case in the US.

This was important in Australia than in the US because Australian import price inflation was close to zero for the 2 years up to the end of 2024. Import prices rose sharply in the first quarter of 2025. What would happen in the second quarter of 2025 and how would it effect inflation I could not tell. The only thing I could do is wait for the Q2 inflation numbers to come out for Australia.

I thought that for this reason and other reasons the RBA would also wait for the Q2 inflation numbers to come out. There were other reasons as well. The Quarterly CPI was a more reliable measure of the CPI and was a better measure of services inflation than the monthly CPI. The result was that RBA did not move and voiced a preference for quarterly measure of inflation over monthly version.

Lets look again at R* or the real level of the Cash rate for Australia .When we look at the average real Cash rate since January 2000 we find an average number of 0.85%. At an inflation target of 2.5 % this suggests this suggest an equilibrium Cash rate of 3.35%

Model of the Australian Cash Rate.
Model of the Australian Cash Rate


What will happen next? We think that the after the RBA meeting of 11 and 12 August the RBA will cut the Cash rate to 3.6%

We think that after the RBA meeting of 8 and 9 December the RBA will cut the Cash rate to 3.35%

Unless Quarterly inflation falls below 2.5% , the Cash rate will remain at 3.35% .

Read more
Investment Watch is a quarterly publication for insights in equity and economic strategy. Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy.

This publication covers

Economics - 'The challenge of Australian productivity' and 'Iran, from the Suez blockade to the 12 day war'
Asset Allocation
- 'Prioritise portfolio resilience amidst the prevailing uncertainty'
Equity Strategy
- 'Rethinking sector preferences and portfolio balance'
Fixed Interest
- 'Market volatility analysis: Low beta investment opportunities'
Banks
- 'Outperformance driving the broader market index'
Industrials
- 'New opportunities will arise'
Resources and Energy
- 'Getting paid to wait in the majors'
Technology
- 'Buy the dips'
Consumer discretionary
- 'Support remains in place'
Telco
- 'A cautious eye on competitive intensity'
Travel
- 'Demand trends still solid'
Property
- 'An improving Cycle'

Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty. The rapid pace of US policy announcements, coupled with reversals, has made it difficult for investors to form strong convictions or accurately assess the impact on growth and earnings. While trade tariffs are still a concern, recent progress in US bilateral negotiations and signs of greater policy stability have reduced immediate headline risks.

We expect that more stable policies, potential tax cuts, and continued innovation - particularly in AI - will support a gradual pickup in investment activity. In this environment, we recommend prioritising portfolio resilience. This means maintaining diversification, focusing on quality, and being prepared to adjust exposures as new risks or opportunities emerge. This quarter, we update our outlook for interest rates and also explore the implications of the conflict in the Middle East on portfolios. As usual, we provide an outlook for the key sectors of the Australian market and where we see the best tactical opportunities.


Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more